Loading...

Home
ETF
PAVM

PAVM

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

PAVM News

PAVmed Secures $30 Million in Series D Preferred Stock Offering

Feb 04 2026PRnewswire

PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans

Jan 22 2026Benzinga

Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%

Jan 21 2026Benzinga

PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%

Jan 21 2026stocktwits

Netflix, Inc. (NFLX) Reports Q4 Earnings Beat but Issues Lower Q1 Guidance, Shares Down 3%

Jan 21 2026Benzinga

Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing

Jan 21 2026seekingalpha

Lucid Diagnostics Secures VA Contract for EsoGuard Test, Expanding Access to 9 Million Veterans

Jan 21 2026Newsfilter

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

Dec 30 2025PRnewswire

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

Dec 30 2025Newsfilter

Lucid Diagnostics Reports 95% Success Rate in 11,991 EsoGuard Tests for Esophageal Cancer Screening

Dec 09 2025Newsfilter

Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

Dec 01 2025NASDAQ.COM

Lucid Diagnostics Recognized as a Top-Ranking Honoree in GenomeWeb's 2025 Best Places to Work

Nov 20 2025Newsfilter

Lucid Diagnostics to Join Canaccord Genuity's MedTech, Diagnostics, and Digital Health & Services Forum

Nov 13 2025Newsfilter

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12 2025PRnewswire

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

Oct 30 2025PRnewswire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Oct 29 2025PRnewswire